Octopus Investments Ltd. announced an investment of £1.7 million into Michelson Diagnostics Ltd., a medical equipment and scanner provider, whose laser scanning technology can image skin and other surface tissue at higher resolutions than ever before. The investment is the 21st deal concluded by investment specialist Octopus this year. Michelson Diagnostics’ VivoSight scanner is used for the non-invasive diagnosis and treatment of non-melanoma skin cancer. (Photo: Michelson Diagnostics) Based on Michelson Diagnostics’ multi-beam optical coherence tomography technology, the VivoSight scanner has the ability to revolutionize the market for the non-invasive diagnosis and treatment of non-melanoma skin cancer. The scanner has won CE and FDA regulatory clearance for clinical use in Europe and the US. It is now being trialed by skin cancer specialists at their clinics. The scanner will enable clinicians to see under the skin surface in real time, to help them determine whether to treat a lesion, what treatment to use, and to show them how far a tumor has spread so that surgery is required only once and conserves healthy tissue. It is anticipated to make non-melanoma skin cancer treatment more efficient and cost-effective. Octopus’ investment will help fund the manufacture and placement of VivoSight scanners with key-opinion-leaders for clinical and economic validation, and will support the growth of the sales infrastructure in the UK and US, said the company. For more information, visit: www.md-ltd.co.uk